ArticleScientific reports2017
Undercarboxylated osteocalcin reverts insulin resistance induced by endoplasmic reticulum stress in human umbilical vein endothelial cells.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 38 citations in OpenAlex.
- Effect of insulin resistance on gonadotropin and bone mineral density in nondiabetic postmenopausal women.Frontiers in endocrinology · 2023Article
- Association of Bone Turnover Markers with Type 2 Diabetes Mellitus and Microvascular Complications: A Matched Case-Control Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- Osteocalcin association with vascular function in chronic kidney disease.Journal of clinical hypertension (Greenwich, Conn.) · 2022Article
- Osteocalcin and the physiology of danger.FEBS letters · 2022Review
- Twelve weeks of a diet and exercise intervention alters the acute bone response to exercise in adolescent females with overweight/obesity.Frontiers in physiology · 2022Article
- Decarboxylated osteocalcin, a possible drug for type 2 diabetes, triggers glucose uptake in MG63 cells.World journal of diabetes · 2021Article
- Endocrine role of bone in the regulation of energy metabolism.Bone research · 2021Review
- Undercarboxylated osteocalcin has no adverse effect on endothelial function in rabbit aorta or human vascular cells.Journal of cellular physiology · 2021Article
- Protective role of osteocalcin in diabetes pathogenesis.Journal of bone and mineral metabolism · 2020Review
- Association between changes in bioactive osteocalcin and glucose homeostasis after biliopancreatic diversion.Endocrine · 2020Observational
- The facts of the matter: What is a hormone?PLoS genetics · 2020Article
- Osteokines and the vasculature: a review of thePeerJ · 2019Article
- Potential Role for Osteocalcin in the Development of Atherosclerosis and Blood Vessel Disease.Nutrients · 2018Review
- Bone mineral density and risk of type 2 diabetes and coronary heart disease: A Mendelian randomization study.Wellcome open research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteocalcin has been considered to be an important regulator of energy metabolism in type 2 diabetes mellitus (T2DM). However, the mechanism underlying the involvement of uncarboxylated osteocalcin in the vascular complications of T2DM is not fully understood. In the present study, we analyzed the potential correlations between uncarboxylated osteocalcin and macro- or microangiopathic complications in subjects with T2DM and tested the impact of uncarboxylated osteocalcin on insulin resistance in human umbilical vein endothelial cells (HUVECs). The results showed that the serum levels of uncarboxylated osteocalcin were lower in subjects with vascular complications of T2DM. Univariate correlation analyses revealed negative correlations between uncarboxylated osteocalcin and waist-to-hip ratio, HbA1c, and HOMA-IR. In in vitro experiments, insulin resistance was induced by applying tunicamycin to HUVECs. Uncarboxylated osteocalcin not only markedly reduced the phosphorylations of PERK and eIF2α, but also elevated the phosphorylations of IRS-1 and Akt, resulting in improvement of insulin signal transduction via PI3K/Akt/NF-κB signaling in HUVECs. Therefore, there is a possible relationship between uncarboxylated osteocalcin and the vascular complications of T2DM. Uncarboxylated osteocalcin partially improves insulin signal transduction via PI3K/Akt/NF-κB signaling in tunicamycin-induced HUVECs, suggesting osteocalcin as a potential treatment for the vascular complications of T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.